Related Experiment Video

Updated: Apr 10, 2026

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

65

Systemic therapy options for advanced gastrointestinal stromal tumors beyond first-line imatinib: a systematic review

Omar Abdel-Rahman1, Mona Fouad2

  • 1Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

Future Oncology (London, England)
|June 16, 2015
PubMed

Insights

For advanced gastrointestinal stromal tumors (GIST) after imatinib, sunitinib shows promise in the second-line setting. Regorafenib is identified as the preferred option for third-line systemic therapy in GIST patients.

Area of Science:

  • Oncology
  • Gastroenterology
  • Pharmacology

Background:

  • Advanced gastrointestinal stromal tumors (GIST) pose treatment challenges beyond initial therapy.
  • Imatinib is a standard first-line treatment, but resistance and progression necessitate further options.

Purpose of the Study:

  • To systematically review and assess evidence for systemic therapies in advanced GIST after first-line imatinib.
  • To identify optimal second- and third-line treatment strategies for GIST patients.

Main Methods:

  • Systematic review of eligible clinical trials.
  • Inclusion of 26 studies in the final analysis.
  • Evaluation of progression-free survival (PFS) and overall survival (OS) data.

Main Results:

  • Second-line therapy: Median PFS ranged from 1.9 to 10 months; median OS ranged from 15 to 62 months.
  • Third-line therapy: Median PFS ranged from 1.8 to 4.6 months; median OS ranged from 8.2 to 19 months.
  • Sunitinib identified as the best second-line option; regorafenib as the best third-line option.

Conclusions:

  • Sunitinib demonstrates efficacy as a second-line systemic therapy for advanced GIST.
  • Regorafenib is the recommended agent for third-line treatment in advanced GIST.
  • Evidence supports sequential systemic therapy approaches for refractory GIST.
Keywords:
GISTimatinibsalvage treatmentsecond linesystemic treatmentthird line

More Related Videos

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

2.7K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K